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Background: Motor and non-motor impairments affect quality of life in individuals with Parkinson’s disease. Our
preliminary research indicates that forced exercise cycling, a mode of exercise in which a participant’s voluntary rate
of exercise is augmented on a stationary cycle, results in global improvements in the cardinal symptoms of Parkinson’s
disease. The objective of the Cyclical Lower Extremity Exercise (CYCLE) trial for Parkinson’s disease is to determine the
effects of forced exercise cycling on motor and non-motor performance when compared to voluntary rate cycling and
a non-exercise control group. Additionally, we plan to identify any associated changes in neural activity determined by
functional magnetic resonance imaging.
Methods/Design: A total of 100 individuals with mild to moderate idiopathic Parkinson’s disease will participate in a
single-center, parallel-group, rater-blind study. Participants will be randomized 2:2:1 into a forced exercise, voluntary
exercise, or no-exercise control group, respectively. Both exercise groups will cycle 3 times per week for 8 weeks at
identical aerobic intensities for 40 minutes, but participants in the forced exercise group will cycle 30% faster than their
voluntary rate by means of an augmented motorized bicycle. Neuroimaging, clinical, and biomechanical assessments
of motor and non-motor performance will be made at baseline both ‘on’ and ‘off’ medication, after four weeks of
exercise (midpoint), end of treatment, 4 weeks after end of treatment, and 8 weeks after end of treatment.
Discussion: CYCLE trial will play a critical role in determining the effectiveness of two different types of aerobic
exercise, forced and voluntary, on motor and non-motor performance in individuals with Parkinson’s disease. Additionally,
the coupling of clinical, biomechanical, and neuroimaging outcomes has the potential to provide insight into
mechanisms underlying change in function as a result of exercise.
Trial registration: Clinicaltrials.gov registration number NCT01636297.
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MethodologyBackground
Parkinson’s disease (PD) is a chronic, progressive neuro-
logical disorder that affects an estimated 4 million indi-
viduals worldwide [1]. Individuals diagnosed with PD
typically experience progressive deficits in motor and
non-motor functions which contribute to diminished
quality of life, cognitive impairments, fatigue, mood* Correspondence: albertj@ccf.org
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unless otherwise stated.disorders, and anxiety [2-5]. Unfortunately, there is no
treatment that can modify the disease process itself.
Current therapies include symptom management through
medical and surgical interventions; however, these treat-
ments are expensive and can cause adverse side effects.
Therefore, the development of a low-cost, non-invasive
treatment that can improve symptoms of PD and improve
quality of life would be valuable.
It has been well-established that exercise in healthy
adults plays a role in decreasing the incidence of cardio-
vascular, metabolic, and musculoskeletal conditions, as
well as preserving cognitive function and preventingtral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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medicine’ for PD, is supported by evidence that regular
exercise may delay the onset of PD symptoms [7], and
can improve motor scores, balance, and quality of gait in
those with the disease [8]. Nevertheless, there is still
much debate over what type of exercise should be pre-
scribed. A recent Cochrane Review notes that due to small
sample sizes, methodological flaws, and a wide range of
exercise interventions, there is insufficient evidence to
recommend one mode of exercise over another [9].
Aerobic exercise has been shown to reduce inflamma-
tion, suppress oxidative stress, and stabilize calcium
homeostasis, which all promote brain health [10]. Look-
ing specifically at the role of aerobic exercise in neuro-
logical conditions, it may induce neuroplastic changes
in the central nervous system (CNS) through the release
of neurotrophic factors, which are capable of signaling
neurons to survive, differentiate, and grow [11]. Animal
models of PD support the importance of aerobic exercise
in the release of neurotransmitters and neurotrophic fac-
tors, specifically brain derived neurotrophic factor and
glial cell derived neurotrophic factor, which have been as-
sociated with positively impacting cognition and motor
function in animal models of PD [12-15].
Previous studies suggests that exercise interventions
must be intense and continuous to elicit benefits on PD
symptoms [6,16]. However, individuals with PD typically
experience varying levels of rigidity and bradykinesia,
which may limit their ability to complete continuous,
high-intensity exercise [17-19]. To address these issues,
a novel mode of aerobic exercise termed forced exercise
(FE) was developed to aid individuals with neurological
deficits to achieve and maintain a high cadence pedaling
rate. Initially, the FE paradigm was implemented using a
tandem stationary cycle where the trainer on the front
of the tandem bicycle pedaled between 80-90 rpms, and
the individual with PD on the back of the bike was
forced to pedal at the same rate due to the pedals on a
tandem bike being mechanically linked by the bike chain
[20,21]. In a preliminary study completed by Alberts and
colleagues, motor outcomes were examined after indi-
viduals with PD completed 8 weeks of cycling using ei-
ther the FE approach or voluntary exercise (VE), where
individuals cycled on a stationary bike at a self-selected
cadence [20,21]. The Unified Parkinson’s Disease Rating
Scale (UPDRS) [22] motor subscale score for individuals
randomized into the FE group improved 41% for rigidity,
38% for tremor, and 28% for bradykinesia. Additionally,
biomechanical analysis of grasping force and torque in-
dicated that FE, but not VE, resulted in an improvement
in the coordination and control of grip and load forces
during the performance of a bimanual object manipula-
tion task [20,21]. Functional connectivity magnetic res-
onance imaging (fcMRI) was conducted during thefollowing conditions: 1) on PD medication, 2) off PD
medication, and 3) off medication after a single bout of
FE. Results demonstrated that FE and PD medication
produce similar brain connectivity responses, and likely
share similar underlying mechanisms [23]. An improve-
ment in upper extremity motor control processes fol-
lowing a lower extremity exercise intervention coupled
with the change in fcMRI indicate that FE is altering
brain structure and potentially function in some man-
ner. However, the specific mechanism and identification
of the phenotype of PD patients that could benefit from
FE is unknown.
Not all studies examining high intensity exercise with
PD have had such promising results. In a 2013 study,
Qutubuddin and colleagues randomized 23 individuals
with PD into a FE and no-exercise control group [24].
After 16 FE sessions, they found no difference between
groups in quality of life or motor outcomes, including
the UPDRS motor assessment [24]. A significant limita-
tion of their study was that they did not use an active FE
intervention. Rather, they used a cycle that could be pro-
grammed to move the pedals at a selected speed, how-
ever, the participants did not have to actively contribute
to the pedaling action. Hence, it was passive high-rate
exercise as opposed to FE as we have previously pub-
lished which requires active participation of the patient.
Additionally, participant heart rate (HR), cadence, and
power were not reported in the results; therefore, it is
not possible to know how much the participants were
contributing or if they were experienced an elevated HR
that was close to an aerobic zone. Shulman, et al. reported
that low-intensity treadmill training produced changes in
a 50-ft fast pace ambulation test and 6 minute walk times
that were not seen in high-intensity treadmill training,
and neither group displayed changes in UPDRS scores
[25]. Notably, the low-intensity group received 50 minutes
of treadmill training, while the high-intensity group re-
ceived only 30 minutes; therefore, it is possible that time
was an important factor in gait changes.
The Cyclical Lower Extremity Exercise for Parkinson’s
(CYCLE) Trial is designed to test the hypothesis that FE
and VE, while both aerobic, produce different clinical
outcomes as a result of differential effects on the CNS.
Specifically, the aims of the CYCLE trial are: 1) To de-
termine the effects of FE and VE on motor function in
individuals with PD; 2) To determine the effects of FE
and VE on non-motor function in individuals with PD;
and 3) To determine the pattern of magnetic resonance
imaging (MRI) activation associated with FE and VE. It
is hypothesized that FE will elicit significantly greater
improvements in clinical and biomechanical measures of
motor and non-motor performance when compared to
voluntary and no-exercise control groups. Further, it is
hypothesized that FE will elicit increased cerebral blood
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ercise, while voluntary and no-exercise groups will result
in no change in the pattern or extent of activation as
seen on neuroimaging.Methods and design
Study design
This single center, prospective, rater-blind, three arm
clinical trial will investigate the efficacy of a FE paradigm
on motor and non-motor symptoms in individuals with
PD. A total of 100 individuals with mild to moderate
idiopathic PD will be enrolled. CYCLE Trial protocol is
approved by the Cleveland Clinic Institutional Review
Board and all participants will sign an informed consent
prior to beginning the study. Written informed consent
was obtained for any photographs that have been taken
for publication. A schematic overview of the enrollment,
testing, and intervention is shown in Figure 1.Figure 1 Study flow diagram outlining the 18 week enrollment.Power analysis
For Aim 1, the UPDRS motor score will be the primary
outcome. Our power analysis was calculated based on
UPDRS motor data from our previous project compar-
ing FE and VE interventions on UPDRS ratings. We ob-
served a mean (95% confidence interval (CI)) reduction
of -5.3 (-18.0, 7.4) in the FE group and 0.4 (-15.3, 16.1)
in the VE group from baseline to end of treatment
(EOT) at 8 weeks. This corresponds to a difference (im-
provement, reduction) in means (95% CI) of -4.9 (-20.6,
10.8), standard deviation (SD) of difference = 8.0, P =
0.004. Assuming similar variability for the current pro-
posal, with N = 40 subjects per exercise group, we will
be able to detect differences of 5.0 or more between
groups on UPDRS with 90% power at the 0.05 signifi-
cance level, adjusting for 3 group comparisons at each of
EOT evaluations. No published data exists for outcomes
in Aim 2 or 3 with respect to exercise and PD. In gen-
eral, with 40 subjects per exercise group, power will be
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tween the groups. For Aims 1-2, comparisons at particular
time points power is 90% to detect differences of 1.3 SD,
applying a Bonferroni correction for analyzing time points
(2 post-intervention times) individually. All calculations
assume Tukey adjustment for comparing the 3 groups.
Subject enrollment
Participants will be recruited via patient education groups,
study literature placement in exam rooms, patient chart
reviews by research personnel, and in-service lectures at
Cleveland Clinic affiliate and non-affiliate hospitals in the
Cleveland-metro area.
Primary inclusion criteria for CYCLE Trial include:
clinical diagnosis of idiopathic PD, between 30 and 75
years of age, not currently engaged in physical therapy
for their PD or another interventional clinical study,
Hoehn and Yahr stage II-III while on antiparkinsonian
medication. Primary exclusion criteria include: presence
of dementia, previous stroke, any medical or musculo-
skeletal contraindications to exercise, and existing car-
diorespiratory disease as determined by American Heart
Association/American College of Sports Medicine exer-
cise pre-participation questionnaire [26,27].
Cardiopulmonary exercise testing
Following completion of initial screening, participants
will undergo cardiopulmonary exercise testing (CPX).
CPX protocol is administered by an exercise physiologist
from the preventative cardiology department of the
Cleveland Clinic. Testing will be completed on a Lode
cycle ergometer using MedGraphics CardiO2/CP system
with Breeze software. The participant will be instructed
to take his/her PD medication as prescribed on the day
of testing. A 12-lead electrocardiogram will be assessed
prior to exercise, continuously during exercise, and dur-
ing exercise recovery. Participants will exercise at an ini-
tial load of 25 Watts, increasing by 25 Watts every two
minutes until 100 Watts, and then increasing by 50
Watts every two minutes until the American College of
Sports Medicine’s Guidelines for Exercise Testing criteria
for test termination are reached [28]. The participant’s
peak volume of oxygen uptake (VO2) will be calculated
as the highest 30 second average of VO2 during the CPX
test. A Cleveland Clinic cardiologist will interpret the re-
sults of the test, and those with normal responses to ex-
ercise will be randomized while those with abnormal
responses will be advised for further medical work up.
Randomization
Participants will be randomized 2:2:1 into FE, VE, or no-
exercise control group. The uneven allocation of sub-
jects was selected due to the promising results of the
preliminary data by Alberts, et al. indicating there is abenefit to cardiovascular exercise that would not been seen
in a control group [20,21]. Enrollment will total 18 weeks:
two weeks allotted for baseline evaluations, 8 weeks of exer-
cise intervention or control period, and 8 weeks for a follow
up period in which the participant is instructed to return to
their baseline level of physical activity.
Voluntary exercise intervention group
Subjects randomized into the VE group will participate
in 3 weekly exercise sessions over the course of 8 weeks
for a total of 24 sessions. Exercise sessions will consist of
a 5-minute warm up, a 40-minute main exercise set, and
a 5-minute cool down on a standard stationary bicycle.
All sessions will be completed under the guidance of an
exercise physiologist. For participants who are decondi-
tioned upon study enrollment, rest breaks will be allowed
for 2 minutes every 10 minutes during the 40-minute
main exercise set. Participants will be asked to pedal at a
self-selected pace, and will be encouraged to achieve their
target HR range, which will be calculated from their rest-
ing and maximal HR during the CPX test using the Kar-
vonen formula at 60-80% of their max exertion [29]. HR,
cadence, and power will be recorded every 5 minutes, and
the rate of perceived exertion will be recorded every 10
minutes. Supervising exercise trainers and study personnel
will be certified in Basic Cardiac Life Support. If a partici-
pant exhibits signs of cardiac distress or hemodynamic
compromise, the exercise session will be stopped immedi-
ately and the on-call physician will be paged to the exer-
cise laboratory. Following completion of the 24 session
exercise intervention, participants will be instructed to re-
sume pre-enrollment activity levels.
Forced exercise intervention group
Participants in the FE group will receive a dose-matched
intervention compared with the VE group. While our
preliminary trials involved tandem cycling, in an attempt
to make the intervention more feasible in a clinical setting,
we have designed a stationary, motorized bike to augment
self-selected cadence. The clear difference between the cyc-
ling groups is that while the VE group will use a standard
stationary bike, participants in the FE group will be using a
standard stationary bicycle that has been retrofitted with a
motor to augment pedaling rate. In order to ensure that the
participant is actively contributing to the pedaling motion,
the algorithm used to control the assisted-cycle is respon-
sive to pedal rate, the torque exerted on the pedals by the
participant, and the torque produced by the motor during
exercise. Based on our preliminary work with FE and PD,
the cadence will be set at a rate that is approximately 30%
greater than the individual’s self-selected pace during the
CPX test [21]. It is important to note that although the par-
ticipant will be cycling at an augmented rate, it is an active,
not passive, activity. Power, cadence, HR, and rating of
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vals as the VE group.
No exercise control group
Participants in the no-exercise control group will be
instructed to maintain their pre-enrollment level of ac-
tivity throughout the duration of their study enrollment.
The study’s exercise physiologist will conduct weekly
phone calls to ensure adherence, itemize participants’
activity levels, and monitor current medication regimes.
Testing and outcome measures
Clinical tests, biomechanical tests, and MRI results will
be compared at the following time points: baseline, mid-
point, EOT, EOT + 4 weeks, and EOT + 8 weeks as
depicted in Table 1. All testing will be completed in the
‘off med’ state, where the participant will be ask to ab-
stain from their antiparkinsonian medication after 8pm
the night preceding testing. The exception is baseline
testing, which will be conducted over 2 days, one day in
the ‘on med’ state and the other in the ‘off med’ state
(randomized). The Research Electronic Data Capture
(REDCap©) Database, a secure electronic database, will
be used to record and store data.
Clinical and biomechanical measures will be used to
assess motor and non-motor outcomes. The primary
clinical motor outcome measure will be the UPDRS
motor subscale, a well-studied test used to obtain a com-
prehensive clinical rating of PD [22]. The rater for this
test will be blind to subject randomization. A secondary
motor outcome will be the Timed Up and Go (TUG) is
a reliable physical performance measure that assesses
the time required for an individual to stand from a chair,
ambulate 3 meters, turn 180 degrees, ambulate back to
the chair, and return to a seated position [30].Table 1 Summary of outcome measures
Assessment Baseline* Basel
Medication Status On Off
UPDRS motor subscale X X
Beck Depression Inventory II X
University of Pennsylvania Smell Identification Test X X
Timed Up and Go X X
Hopkins Verbal Learning Test X X
Parkinson’s Disease Questionnaire-39 X
Trail Making Test X X
Simple & Choice Reaction Task X X
Processing Speed Test X X
Postural Sway X X
Nine Hole Peg Test X X
MRI X X
* Baseline ‘on meds’ and ‘off meds’ are randomly assigned to be testing day 1 or 2.Other clinical non-motor assessments will include the
Parkinson’s Disease Questionnaire-39 (PDQ-39), Univer-
sity of Pennsylvania Smell Identification Test (UPSIT),
Hopkins Verbal Learning Test, and the Beck Depression
Inventory II (BDI-II). The PDQ-39 is a 39-item ques-
tionnaire that assesses the quality of life in individuals
with PD [31]. In the UPSIT, which is used to assess
hyposmia, the participant is asked to identify 40 odor-
ants presented on microencapsulated booklet [32]. The
Hopkins Verbal Learning Test is used to assess verbal
memory of the participant [33], and the BDI- II ques-
tionnaire assesses depressive symptomology [34].
In an effort to gather biomechanical outcomes, several
novel electronic mobile applications will be utilized. The
modules, developed on the Apple iPad, include the Trail
Making Test, Simple Reaction Task, Choice Reaction
Task, Processing Speed Test, and a measure of postural
sway in standing. The utilization of the iPad modules to
assess cognitive and motor function provides a method
of obtaining biomechanical data in a cost and time effi-
cient manner compared to traditional biomechanical mea-
sures. Briefly, the Trail Making Test module is based on a
widely-used neuropsychological assessment designed to
evaluate executive function that involves connecting num-
bers (1-2-3…) and a number/letter sequence (1-A-2-B….)
that are arranged on paper [35]. In the case of the app, the
targets are arranged in a similar manner while using Fitts’
Law to ensure the segment of difficulty is matched across
the paper and pencil form compared to the iPad version
[36]. The electronic version administered on the iPad
samples the time and X-Y position data at 60Hz which is
then used to determine when the patient is moving versus
searching for the next target [37]. The Simple Reaction
Task module provides quantitative data on information
processing by measuring the time between the presentationine* Mid-point EOT EOT + 4 weeks EOT + 8 weeks
Off Off Off Off
X X X X
X
X X
X X X X
X X X X
X
X X X X
X X X X
X X X X
X X X X
X X X X
X X
Figure 2 The iPad’s gyroscope and accelerometer capture linear
and rotational movement to calculate volume of postural sway
when belted to the waist of the participant. In this figure, the iPad is
counting down from 30 seconds as the participant performs the
following stances: 1) double leg stance, firm surface, eyes open; 2)
double leg stance, firm surface, eyes closed.
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Choice Reaction Task module measures reaction time with
more complex thinking, as one of two stimuli is randomly
activated and the participant is timed from presentation to
selection of the stimuli [37]. The technology of the iPad al-
lows the reaction time speed to be measured accurately to
the millisecond. The Processing Speed Test module is a
modified, electronic version of the paper-and-pencil
symbol-digit matching test which assesses complex at-
tention and information processing speed [38,39]. For
the module, the participant is presented with nine symbols
matched with Arabic numerals 1-9. Below the key, sym-
bols alone are presented to the participant. The partici-
pant is asked to correctly match as many symbols as
possible to the corresponding numeral in 90 seconds.
As a biomechanical measure of balance, the gyroscope
and accelerometer of the iPad will measure volume of
postural sway [37,40-43]. We have validated the use of
the iPad to characterize balance in young, healthy older
adults, and individuals with PD [37,40-43]. Attached to
the waist of the participant, the iPad captures linear and
rotational movement to calculate the volume of postural
sway (Figure 2). The postural sway test consists of a 30-
second trial on the following conditions: 1) firm surface,
double leg stance, eyes open; 2) firm surface, double leg
stance, eyes closed.
The Nine Hole Peg Test (NHPT) will be used as a
measure of manual dexterity [44]. Consistent with our
effort to objectify our outcome measures, the NHPT
module is an electronic form of the traditional NHPT
(Figure 3). Participants are instructed to pick up indi-
vidual pegs from a dish, place them in the nine peg
slots until all slots are filled, and then remove the pegs.
The electronic version is an overlay mold over the iPad
and has been shown to be reliable in individuals with
multiple sclerosis [39]. The iPad capacitive touch screen
detects the time between each peg insertion and removal,
which provides a more precise temporal-spatial under-
standing of manual dexterity than the traditional measure.
MRI data collection
For this study, structural MRI, functional MRI (fMRI),
fcMRI and cerebral blood flow (CBF) data will be ac-
quired on four occasions: Baseline (on and off antipar-
kinsonian medication), EOT, and EOT + 4 weeks. The
structural scan is a T1-weighted anatomic image for
identifying brain anatomy. The fMRI and fcMRI scans
will be acquired with blood oxygen level-dependent
(BOLD)-weighted echoplanar imaging scans. Two fcMRI
scans will be acquired while subjects rest in the scanner
with eyes closed. Two fMRI scans will be acquired in each
session while subjects complete finger tapping in the fol-
lowing self-paced repeating sequence: digit 1, digit 3, digit
5, digit 2, digit 4 with each limb (left and right limbs, inrandom order) in a block paradigm (alternating 48
second-long blocks of tap and rest phases, repeated 4.5
times) to determine the relationship between changes in
upper extremity motor performance and pattern of brain
activation. Additional measures recorded for exploratory
purposes include fcMRI between nodes of the putative
motor network.
Data analysis
Participants in all three groups will be compared de-
scriptively on potentially confounding baseline variables
(i.e., age, disease severity, and levodopa equivalent daily
dose (LEDD)) to assess the extent of any imbalance
across groups. Baseline variables in which there appears
to be a clinically important baseline difference, or in
which the standardized difference (absolute value of dif-
ference in means divided by pooled SD) between any 2
groups is greater than 10% will be included as covariates.
P-values from these baseline variable comparisons will
Figure 3 A transparent plastic overlay attaches to the iPad to create
the electronic version of the NHPT. The participant performs the first
segment of the NHPT by transferring the pegs from a dish to one of
the 9 holes, removing the pegs, and returning them to the dish,
which is measure of in-hand manipulation and manual dexterity.
The second part of the test involves transferring pegs to and from a
row (pictured on the right of the iPad screen below) rather than the
dish to calculate transport time only. The capabilities of the iPad allows
for detection of the time between each peg insertion and removal.
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ment, as that criterion can be misleading.
The FE, VE, and the no-exercise control groups will be
compared on each outcome of interest (motor, non-
motor) using repeated measures analysis of covariance.
For motor and non-motor outcomes, groups will be
compared on outcomes at the mid-treatment, EOT,
EOT + 4 weeks, and EOT + 8 weeks adjusting for the
baseline (on and off medication) period as a covariate.
The effects of group, time, and the group-by-time
interaction will be assessed for each outcome. In the
case of a significant interaction, the groups will be
compared at each time point. Tukey’s correction for
multiple comparisons will be used. Data will be trans-
formed as needed to meet model assumptions. In
addition to p-values, the estimated treatment effect
and its 95% CI will be of interest as these data will aid
in formulating exercise recommendations and potential
benefits. For each hypothesis, significance level will be set
at 0.05. Each participant’s change in fitness based on
change in peak VO2 from CPX testing will be used as a
covariate. This will remove the effect of possible differ-
ences in improvement in fitness level across the groups
from confounding the results. Correlation between LEDD
and the time spent within target HR zone during training,
amount of work performed, and change in primary out-
come variables in motor and non-motor outcomes will
be assessed. If the LEDD is significantly correlated with
these outcomes, it will be included as a covariate in the
related analysis.MRI data
Functional imaging data collected during the motor
tasks will be retrospectively motion corrected with a
slice-based second-order motion model [45,46] in parallel
with physiologic noise regression [47], spatially filtered
[48] and analyzed for task-related activation using a least-
squares fit of the voxel-level BOLD signal to a reference
function generated from the task design [49]. The result
will be a whole brain map of Student’s t-values reflecting
the response of each voxel for each task. A paired t-test of
the total volume of activation above a t-value of 3.5
(p < 0.001, uncorrected) in the supplemental motor area
will be calculated in all subjects. Correlation will be calcu-
lated between the change in activation volume of the
supplemental motor area and subcortical structures of
interest (globus pallidus, putamen, and thalamus) for
each subject and the corresponding biomechanical mea-
sures during a finger tapping task during the scan and
UPDRS rating.
Arterial spin labeling data and CBF measurement
Exercise may have an effect on baseline CBF. Basal CBF
will affect the amplitude of the BOLD signal in response
to a given neuronal activation level. In order to control
for this possible confound to our measurement, we will
measure basal CBF during each imaging session in order
to 1) assess whether there are observed baseline CBF
changes with the proposed exercise regimen, and 2) to
permit the inclusion of this measure in a population
analysis in order to control for this effect. A Q2TIPS ar-
terial spin labeling (ASL) scan will be used to measure
baseline CBF [50]. The ASL scan parameters are as fol-
lows: TE/TR/Flip = 2300/13/80, 12 axial slices 5mm
thick, 1mm slice gap, FOV = 256x256, matrix = 64x64,
TI1/TI2/SST = 700/1400/1100, bandwidth = 150kHz,
repetitions = 139, Tag Slab = 100mm with 25mm gap.
Adverse events
Serious adverse events, defined as an adverse experi-
ence that results in death, life-threatening experience,
hospitalization, or significant disability, will be reported to
the Cleveland Clinic Institutional Review Board within 10
working days. Non-serious adverse events will be reported
annually. At the time of any adverse event, the event will
be formally recorded by a member of the study team and
reviewed by the primary investigator, who will determine
if protocol or informed consent changes are necessary.
Discussion
Although exercise prescription has become an increasing
popular treatment for individuals with PD, there are
currently no specific recommendations regarding mode,
intensity, and duration [9]. In this protocol, we are pre-
scribing a very specific mode, intensity, and duration of
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cise prescription. Specifically with aerobic exercise, it
has been noted that there are gaps in literature on the
immediate and long-term effects on PD symptoms [15].
Our follow-up periods include assessments up to 8
weeks following cessation of the intervention to deter-
mine the interim effects of this form of exercise.
While the UPDRS is a readily accepted outcome meas-
ure with PD; there is a lack of biomechanical outcome
measures used in clinical trials for neurological popula-
tions. Through literature review, previous experience, and
knowledge of the disease symptomology, the selected out-
comes are comprehensive, objective, and systematic which
will provide the opportunity to truly understand the clin-
ical and behavioral effects of FE and VE on PD function.
By automating several outcome measures to provide a
more detailed and precise data collection tool, there is the
potential for further understanding of PD symptomology.
For example, in the Trail Making Test, the movement and
dwell time can be separated, thus allowing the investiga-
tors to determine if time spent on a test is due to move-
ment time, indicating a motor impairment, or dwell time,
indicating a cognitive impairment from the individual pro-
cessing which digit or number is next in the sequence.
Likewise with the iPad version of the NHPT, the partici-
pant performs 2 different versions of the test (Figure 3).
As a measure of in-hand manipulation, the first version
consists of having the participant grasp, manipulate, and
transfer the pegs from a dish to one of the 9 holes, remove
the pegs, and return them to the dish. The second part of
the test involves transferring pegs to and from a row,
rather than the dish, to calculate transport time only. This
differentiation between in-hand manipulation and transfer
time could be helpful in differentiating between deficits.
Several of these iPad modules, including the postural
sway test, NHPT, and Processing Speed Test, have been
found to be reliable, sensitive, and clinically meaningful
in individuals with multiple sclerosis [39]. This method
of standardized testing, if found to be reliable and feas-
ible in individuals with PD, will provide further evidence
that objective, quantitative outcomes that can be used in
both a research and a clinical setting are adventitious for
neurological populations.
CYCLE Trial has the potential to make a unique
contribution through the neuroimaging component.
We have published researched that supports the bene-
fit of a one-time bout of cycling on motor cortex func-
tional connectivity; [23] however, the long-term effects
of exercise on CNS connectivity is not known. By con-
ducting imaging in various on and off-medication
states at baseline, EOT, and EOT + 4 weeks, this study
will provide insight into the potential neurophysiological
CNS changes that exercise can produce in individuals
with PD.Overall we feel that the results of this study have the po-
tential to directly impact patient care and will add to a
body of evidence that challenges clinicians to view exer-
cise as medicine for individuals with PD.
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